First patient enrolled in Diamyd Medical's Phase III trial DIAGNODE-3
The first patient has now received its first intralymphatic injection of Diamyd[®] in the precision medicine Phase III trial DIAGNODE-3. The trial will include approximately 330 patients aged 12 to 29 years newly diagnosed with Type 1 Diabetes who carry the genetically defined haplotype HLA DR3-DQ2.“The fact that the first patient is now enrolled in DIAGNODE-3 is a major milestone for the therapeutic diabetes vaccine Diamyd," says Ulf Hannelius, CEO of Diamyd Medical. “The Phase III trial is based on decisive scientific achievements in precision medicine, robust data, a unique and safe
